Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

BACKGROUND: The hepatitis C virus (HCV) NS5A inhibitor ABT-267 (ombitasvir, OBV), the HCV NS4/4A protease inhibitor ABT-450 (paritaprevir, PTV), the CYP3A inhibitor ritonavir (r) and the non-nucleoside NS5B polymerase inhibitor ABT-333 (dasabuvir, DSV) (OBV/PTV/r + DSV) with or without ribavirin (RB...

Descripción completa

Detalles Bibliográficos
Autores principales: Loo, Nicole, Lawitz, Eric, Alkhouri, Naim, Wells, Jennifer, Landaverde, Carmen, Coste, Angie, Salcido, Rossalynn, Scott, Michael, Poordad, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Clinical Trials Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526152/
https://www.ncbi.nlm.nih.gov/pubmed/31143073
http://dx.doi.org/10.3748/wjg.v25.i18.2229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526152/
https://www.ncbi.nlm.nih.gov/pubmed/31143073
http://dx.doi.org/10.3748/wjg.v25.i18.2229

Ejemplares similares